Why Prioritizing Adherence Is a Strategic Imperative

Adherence must shift

By 2030, global BioPharma R&D investment is projected to reach $343 billion, with 45–75% allocated to clinical studies.

Despite this investment:

• More than 85% of studies struggle to retain sufficient participants
• 95% fail to meet original timelines and budgets
• Early drop-out remains stubbornly stable

This signals a structural issue.

Efforts to improve patient centricity have often focused on experience and convenience. While important, these measures do not systematically address behavioral drivers of adherence.

True improvement requires:

• Predictive modeling
• Continuous risk monitoring
• Personalized intervention pathways
• Structured adherence governance

Adherence must shift from reactive mitigation to proactive management.